On this page
Sun Pharma Q1FY27 profit rises 27% as India formulations grow 16%
Our read
Sun Pharma's India franchise is likely to become a larger earnings stabilizer, but sustained share gains will determine whether the Q1 profit acceleration is repeatable.
For operators
Sun Pharma’s 16% growth in India formulations and 8.5% domestic market share signal sustained demand for pharmacy partners and strong availability of its branded portfolio.
Watch
Further movement in domestic market share above 8.5%, especially in chronic and specialty segments.
Ask next
The report,
Sun Pharma reported 27% YoY Q1FY27 profit growth as India formulations rose 16% to Rs 5,475 crore. Its domestic market share reached 8.5%, supported by five product launches. The Organon acquisition remains on track for early-2027 completion.
Reported figures
From the report. Source details below
| Q1FY27 net profit: | Rs 2,894.79 crore, up 27% YoY |
|---|---|
| Q1FY27 revenue: | Rs 15,299.88 crore, up 10.46% YoY |
| India formulations share of consolidated sales: | 36.1% |
| India market share: | 8.5%, versus 8.2% a year earlier |
| EBITDA: | Rs 4,418 crore, up 2.7% YoY |
| EBITDA margin: | 28.9% |
| Exceptional acquisition-related charge: | about Rs 204 crore |
Also in the report
- Five new domestic products launched
Why it matters to operators
Sun Pharma’s faster-growing domestic formulations business and rising 8.5% market share strengthen its position for India-focused brand, distribution, and portfolio partnerships.
What to watch next
- Whether India formulations growth stays above 12-15% over the next two quarters.
- Gross-margin and EBITDA-margin trends indicating whether growth is mix-led or being bought through higher selling expenses.
- US formulation sales, specialty portfolio performance and new product approvals.
- Any USFDA inspection observations, warning letters or manufacturing remediation disclosures.
- Competitor actions on pricing, doctor engagement and trade incentives in key Indian therapy areas.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Increase promotion and field-force coverage in high-growth chronic therapy categories where domestic scale can be converted into prescription share.
- Use improved domestic profitability to accelerate branded launches, specialty products and selective bolt-on acquisitions.
- Defend distributor and pharmacy availability to prevent stock-outs as India formulations volumes rise.
- Emphasize India-market momentum in guidance while managing expectations for US generics, specialty sales and regulatory expenses.
The counter-case
The case against this reading — not reported by the source.
The 16% India formulations growth is strong, but it may not be enough to justify a broad earnings-growth narrative if profit expansion was aided by mix, currency, tax, one-offs, or lower operating costs rather than durable volume-led demand. Domestic growth can also normalize against a favorable base, while pricing pressure, competition in chronic therapies, and regulatory or US-generic headwinds could constrain consolidated profitability.